Bisphosphonates as cancer drugs

Hospital Practice

Volumn 34, Issue 5, 1999, Pages 81-94

  Mundy, Gregory R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; RISEDRONIC ACID; TRANSFORMING GROWTH FACTOR BETA;

BONE METASTASIS; BONE REMODELING; BREAST CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; MYELOMA; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; REVIEW;

EID: 0033562873     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: 10.3810/hp.1999.05.141     Document Type: Review

References (8)

1. Berenson JR et al: Efficacy of pamidronate In reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488,1996
2. Diel IJ et al: Reduction In new metastases in breast cancer with adjuvant clodronate treatment. New Engl J Med 339:357, 1998
3. Guise TA, Mundy GR: Cancer and bone. Endocrine Reviews 19:18, 1998
4. Hortobagyl GN et al: Efficacy of pamidronate in reducing skeletal complications In patients with breast cancer and lytic bone metastases. New Engl J Med 335:1785, 1996
5. Massagué J: TGF-β signal transduction. Annu Rev Biochem 67:753, 1998
6. Mundy GR, Yoneda T: Bisphosphonates as anticancer drugs. New Engl J Med 339:398, 1998
7. Sasaki A et al: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone In nude mice. Cancer Res 55:3551, 1995
8. Yin JJ et al: TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development J Clin Invest 103:197, 1999